Hepatocellular carcinoma associated with long-term cyclophosphamide therapy for Wegener granulomatosis

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

The development of hepatocellular carcinoma (HCC) requires persistent hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. The other origins are extremely rare. A 63-year-old woman was admitted to our hospital for work-up of hepatic mass. She took cyclophosphamide for Wegener granulomatosis for 21 years. Serum HBV and HCV markers were negative. A diagnosis of HCC was made by the imaging findings, and an extended left lobectomy of the liver was performed. Histologically, the tumor was diagnosed as moderately differentiated HCC. We thus considered the HCC in this case as a complication of the long-term cyclophosphamide by the absence of known causes of HCC.

Cite

CITATION STYLE

APA

Okano, A., Matsusue, R., Takakuwa, H., & Nishio, A. (2003). Hepatocellular carcinoma associated with long-term cyclophosphamide therapy for Wegener granulomatosis. Internal Medicine, 42(5), 406–409. https://doi.org/10.2169/internalmedicine.42.406

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free